WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

In Section A, individuals will receive distinctive doses and schedules of oral ABBV-744 pill to discover Protected dosing regimen. Additional contributors might be enrolled at the discovered monotherapy dosign routine. In Phase B, members will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, contributors